Terns Pharmaceuticals, Inc. EV/EBIT

EV/EBIT of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBIT growth rates and interactive chart. EV/EBIT is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes (EBIT), but after Depreciation and Amortization.. The EV/EBIT ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBIT compared to a stock’s historical average or industry can indicate undervaluation. EV/EBIT takes into account the reinvestment needs of a business (depreciation, amortization).


Highlights and Quick Summary

Current EV/EBIT of Terns Pharmaceuticals, Inc. is 0.0 (as of December 31, 2021)
  • EV/EBIT for the quarter ending December 31, 2021 was 0.0
  • Annual EV/EBIT for 2021 was 0.0
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBIT of Terns Pharmaceuticals, Inc.

Most recent EV/EBITof TERN including historical data for past 10 years.

Interactive Chart of EV/EBIT of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. EV/EBIT for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0 0.0

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.